- Home
- SERA vs PROK Comparison
SERA vs PROK Comparison
Compare SERA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERA
- PROK
- Stock Information
- Founded
- SERA 2008
- PROK 2015
- Country
- SERA United States
- PROK United States
- Employees
- SERA N/A
- PROK N/A
- Industry
- SERA Precision Instruments
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SERA Health Care
- PROK Health Care
- Exchange
- SERA Nasdaq
- PROK Nasdaq
- Market Cap
- SERA 258.3M
- PROK 220.6M
- IPO Year
- SERA 2021
- PROK N/A
- Fundamental
- Price
- SERA $6.74
- PROK $1.98
- Analyst Decision
- SERA
- PROK Buy
- Analyst Count
- SERA 0
- PROK 5
- Target Price
- SERA N/A
- PROK $4.50
- AVG Volume (30 Days)
- SERA 57.4K
- PROK 372.8K
- Earning Date
- SERA 11-06-2024
- PROK 11-12-2024
- Dividend Yield
- SERA N/A
- PROK N/A
- EPS Growth
- SERA N/A
- PROK N/A
- EPS
- SERA N/A
- PROK N/A
- Revenue
- SERA $94,000.00
- PROK N/A
- Revenue This Year
- SERA N/A
- PROK N/A
- Revenue Next Year
- SERA $2,018.04
- PROK N/A
- P/E Ratio
- SERA N/A
- PROK N/A
- Revenue Growth
- SERA N/A
- PROK N/A
- 52 Week Low
- SERA $1.65
- PROK $1.12
- 52 Week High
- SERA $12.36
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- SERA 47.81
- PROK 57.87
- Support Level
- SERA $7.56
- PROK $1.49
- Resistance Level
- SERA $8.78
- PROK $1.83
- Average True Range (ATR)
- SERA 0.58
- PROK 0.11
- MACD
- SERA 0.03
- PROK 0.04
- Stochastic Oscillator
- SERA 34.36
- PROK 96.00
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.